SCHEMBL2250573

SCHEMBL2250573

CC(=O)N1C[C@@H](C)N(Cc2cccc(NC(=O)Nc3ccnc(C)c3)c2F)[C@@H](C)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
CCR3 P51677 2/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 1/20 0.37
ROCK2 O75116 1/20 0.37
LIMK1 P53667 1/20 0.37
MTOR P42345 2/20 0.36
TP53 P04637 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654461 0.94 SMARCA2 (0.40) SMARCA2SMARCA4KMT2AMEN1MAPT
SCHEMBL2254757 0.89 SMARCA2 (0.39) SMARCA2SMARCA4KMT2AMEN1MAPT
SCHEMBL2254860 0.89 SMARCA2 (0.39) SMARCA2SMARCA4KMT2AMEN1MAPT
SCHEMBL23573782 0.86 NPSR1 (0.42) KMT2AMEN1MAPTMAPK8MAPK9
SCHEMBL2251440 0.86 SMARCA2 (0.39) SMARCA2SMARCA4KMT2AMEN1MAPT
SCHEMBL5016707 0.84 SMARCA2 (0.39) SMARCA2SMARCA4KMT2AMEN1MAPT
SCHEMBL5016676 0.84 SMARCA2 (0.39) SMARCA2SMARCA4KMT2AMEN1MAPT
SCHEMBL16198776 0.84 RORC (0.41) SMARCA2SMARCA4CCR3RAB9ANPC1
SCHEMBL16198772 0.84 RORC (0.46) SMARCA2SMARCA4KMT2AMEN1MAPT
SCHEMBL402498 0.83 CACNA1G (0.45) KMT2AMEN1MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989455-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2011-08-02 US claimed
EP-1962852-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP claimed
US-20070197497-A1 Compounds, compositions and methods CYTOKINETICS, INC. 2007-08-23 US claimed
WO-2007078839-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2007-07-12 WO claimed
EP-1962852-B1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS INC (US) 2017-01-25 EP disclosed
US-7989455-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2011-08-02 US disclosed
EP-1962852-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP disclosed
US-20070197497-A1 Compounds, compositions and methods CYTOKINETICS, INC. 2007-08-23 US disclosed
WO-2007078839-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197497-A1 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 SMARCA2 959/4885SMARCA4 964/4885KMT2A 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.